CF764E50-B0F9-44DE-8B48-F8F5A8920240
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 122.634691195795
- age_years
- 38
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.470
- UV_RESPONSE_DN+0.457
- OXIDATIVE_PHOSPHORYLATION+0.433
- HEDGEHOG_SIGNALING+0.397
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.358
- MTORC1_SIGNALING+0.356
- TGF_BETA_SIGNALING+0.356
- APOPTOSIS+0.338
- INTERFERON_ALPHA_RESPONSE+0.337
- ADIPOGENESIS+0.336
Top 10 suppressed
- E2F_TARGETS-0.097
- SPERMATOGENESIS-0.088
- IL6_JAK_STAT3_SIGNALING-0.048
- KRAS_SIGNALING_DN-0.031
- COAGULATION-0.026
- MYOGENESIS-0.003
- ANGIOGENESIS+0.022
- G2M_CHECKPOINT+0.039
- DNA_REPAIR+0.044
- IL2_STAT5_SIGNALING+0.067
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-5324-01A-01R-1686-07 | — | — | 0.875 |
| 2 | 0F8847C7-545C-4C3C-B3D0-0681C9480712 | — | — | 0.871 |
| 3 | 69A8CCB7-91F2-475C-8A31-64CD4E075090 | — | — | 0.865 |
| 4 | 077523A7-E1C9-4E9F-8C9F-B9F647B4DF7C | — | — | 0.851 |
| 5 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.849 |
| 6 | 23B8A53B-83FD-47BB-AD6E-184E11B1E957 | — | — | 0.846 |
| 7 | 37586AAC-159B-41F9-9078-C2F7888753AC | — | — | 0.845 |
| 8 | A7C71CEF-A5C7-4BAC-9090-9808B029190B | — | — | 0.837 |
| 9 | TCGA-ZF-AA56-01A-31R-A39I-07 | — | — | 0.834 |
| 10 | 106E2A94-0366-4D5E-894F-41117C78E18C | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.457 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.433 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.397 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.358 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.356 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.356 | Inavolisib | — uncovered |
| APOPTOSIS | 0.338 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.337 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.336 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.335 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.317 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.305 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.301 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.296 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.294 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.294 | Remibrutinib | — uncovered |
| PEROXISOME | 0.276 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.274 | Idelalisib | — uncovered |